S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
NASDAQ:HSCS

Heart Test Laboratories - HSCS Stock Forecast, Price & News

$2.24
-0.09 (-3.86%)
(As of 08/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.20
$2.40
50-Day Range
N/A
52-Week Range
$1.15
$6.00
Volume
153,565 shs
Average Volume
1.70 million shs
Market Capitalization
$18.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
HSCS stock logo

About Heart Test Laboratories (NASDAQ:HSCS) Stock

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional 12-lead resting ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

Analyst Upgrades and Downgrades

Separately, Benchmark assumed coverage on Heart Test Laboratories in a research report on Monday, August 8th. They issued a "speculative buy" rating and a $8.00 price objective for the company.

Heart Test Laboratories Stock Performance

Shares of Heart Test Laboratories stock opened at $2.33 on Thursday. Heart Test Laboratories has a fifty-two week low of $1.15 and a fifty-two week high of $6.00.

Receive HSCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heart Test Laboratories and its competitors with MarketBeat's FREE daily newsletter.

HSCS Stock News Headlines

See More Headlines
Receive HSCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heart Test Laboratories and its competitors with MarketBeat's FREE daily newsletter.

HSCS Company Calendar

Today
8/18/2022
Fiscal Year End
4/30/2023

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HSCS
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+257.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$18.45 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Andrew Simpson (Age 53)
    CEO, Pres & Chairman of Directors
    Comp: $25.81k
  • Ms. Danielle Watson (Age 40)
    CFO & Treasurer
    Comp: $142.71k
  • Mr. Mark T. Hilz (Age 63)
    COO, Sec. & Director
    Comp: $111.01k













HSCS Stock - Frequently Asked Questions

Should I buy or sell Heart Test Laboratories stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heart Test Laboratories in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" HSCS shares.
View HSCS analyst ratings
or view top-rated stocks.

What is Heart Test Laboratories' stock price forecast for 2022?

1 analysts have issued twelve-month price objectives for Heart Test Laboratories' stock. Their HSCS share price forecasts range from $8.00 to $8.00. On average, they expect the company's share price to reach $8.00 in the next year. This suggests a possible upside of 243.3% from the stock's current price.
View analysts price targets for HSCS
or view top-rated stocks among Wall Street analysts.

How have HSCS shares performed in 2022?

Heart Test Laboratories' stock was trading at $2.02 at the beginning of 2022. Since then, HSCS stock has increased by 15.3% and is now trading at $2.33.
View the best growth stocks for 2022 here
.

When did Heart Test Laboratories IPO?

(HSCS) raised $9 million in an initial public offering (IPO) on Wednesday, June 15th 2022. The company issued 1,800,000 shares at a price of $4.50-$5.50 per share. The Benchmark Company acted as the underwriter for the IPO.

What is Heart Test Laboratories' stock symbol?

Heart Test Laboratories trades on the NASDAQ under the ticker symbol "HSCS."

Who are Heart Test Laboratories' major shareholders?

Heart Test Laboratories' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Jane Street Group LLC (0.18%).

How do I buy shares of Heart Test Laboratories?

Shares of HSCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Heart Test Laboratories' stock price today?

One share of HSCS stock can currently be purchased for approximately $2.33.

How much money does Heart Test Laboratories make?

Heart Test Laboratories (NASDAQ:HSCS) has a market capitalization of $19.20 million.

How can I contact Heart Test Laboratories?

The official website for the company is heartsciences.com. The company can be reached via phone at 682-237-7781 or via email at hscs@crescendo-ir.com.

This page (NASDAQ:HSCS) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.